Drug intelligence / Profile preview

MB-GBM-102

Development stage: Preclinical
Lead developer: Mercury Bio
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

MB-GBM-102 is a preclinical nanobody-based therapeutic being developed by Mercury Holdings (Mercury Bio) for the treatment of glioblastoma. As an intracellular immunotherapeutic, it is designed to leverage Mercury Bio's platform for delivering functional proteins across the blood-brain barrier and into cells. The therapy aims to target specific, though currently undisclosed, tumor-relevant pathways within the glioblastoma microenvironment to inhibit tumor growth or induce cell death. Given the company's focus, MB-GBM-102 likely utilizes a specialized delivery system to reach intracellular targets that are typically inaccessible to conventional antibody-based therapies.

Beyond the preview

Go deeper on MB-GBM-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-GBM-102.

Explore the full profile